Janssen: FDA Approves Darzalex Faspro in Combination with Pomalidomide and Dexamethasone for Multiple Myeloma
July 12 2021 - 9:08AM
Dow Jones News
By Michael Dabaie
Johnson & Johnson's Janssen Pharmaceutical Cos. said the
U.S. Food and Drug Administration approved Darzalex Faspro in
combination with pomalidomide and dexamethasone for patients with
blood cancer multiple myeloma after a first or subsequent
relapse.
Janssen said the approval was for the treatment of adult
patients with multiple myeloma who have received at least one prior
line of therapy, including lenalidomide and a proteasome
inhibitor.
The approval marks the sixth indication for Darzalex Faspro in
the treatment of multiple myeloma.
Janssen Biotech Inc. and Genmab A/S in August 2012 entered into
a worldwide agreement, which granted Janssen an exclusive license
to develop, manufacture and commercialize daratumumab.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 12, 2021 09:01 ET (13:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024
